Source: Annual Congress 2011 - Clinical features of human pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
O. Sitbon, A. Yaïci, L. Rottat, V. Cottin, E. Bergot, G. Prévot, V. Gressin, M. Humbert, G. Simonneau (Clamart, Lyon, Caen, Toulouse, Paris, France). The changing picture of patients with pulmonary arterial hypertension (PAH) in France. Eur Respir J 2011; 38: Suppl. 55, 4913

Member's Comments

No comment yet.

Related content which might interest you: 6MWD in patients with pulmonary arterial hypertension (PAH) Source: Eur Respir J 2003; 22: Suppl. 45, 464s Year: 2003 Is there a fixed relationship between the mean and systolic pulmonary artery pressures in idiopathic pulmonary arterial hypertension (IPAH) and proximal chronic thromboembolic pulmonary hypertension (CTEPH) Source: Annual Congress 2009 - Pulmonary embolism Year: 2009 Pulmonary arterial hypertension (PAH) in patients with lung sarcoidosis (LS) Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008 Comparison of subcutaneous (sc) treprostinil use for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in 2 Belgian centers Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease Year: 2010 Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Initial experience of sildenafil in patients with congenital heart disease (CHD) associated pulmonary arterial hypertension (PAH) Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006 Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017 Clinical sildenafil use in Belgian patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010 Selexipag real-world experience in patients over 75 yrs with pulmonary arterial hypertension (PAH) Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021 Patterns of mean pulmonary artery pressure (mPAP)-flow relation changes following chronic therapy in idiopathic pulmonary arterial hypertension (IPAH) Source: Eur Respir J 2006; 28: Suppl. 50, 427s Year: 2006 Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009 Contrasting physiological responses to the six minute walk test in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH) Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Pulmonary arterial hypertension in children Source: Eur Respir J 2003; 21: 155-176 Year: 2003 Macitentan for pulmonary arterial hypertension (PAH): Early clinical experience of 94 patients Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Patterns of therapy with sildenafil among patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Impact of pulmonary arterial hypertension (PAH) on the lives of patients and carers Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 Exhaled breath olfactory signature of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Relationship between comorbidities and quality of life perceived by patients diagnosed with pulmonary hypertension: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2019 – Haemodynamics and chronic thromboembolic pulmonary hypertension Year: 2019 An international survey of current pulmonary arterial hypertension (PAH) management Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012